CHRS Coherus BioSciences Inc.

Coherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference

Coherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. EST / 7:50 a.m. PST.

The audio portion of the Company presentation will be available on the investors page of the Coherus BioSciences website at .

About Coherus BioSciences, Inc.

Coherus is a leading commercial-stage biosimilar company dedicated to expanding access to high-quality therapeutics that can have a major impact on patients’ lives and to delivering significant savings to the health care system. For additional information, please visit .



Contact

McDavid Stilwell
EVP, Corporate Development, IR and Financial Strategy 
Coherus BioSciences, Inc.
 
+1 (650) 395-0152
EN
05/01/2021

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Report Third Quarter 2025 Financial Results on Nov...

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on following the conclusion of the live conference call. Con...

October 30, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its presentations at the following upcoming conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025, at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific TimeJefferies Global Healthcare Conference in London, England on Tuesday, November 18, 2025, at 10:30 a.m. Greenwich Mean Time / 5:30 a.m. Eastern TimeBaird Biotech Discovery Series takes pl...

October 23, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology Announces Poster Presentation at the 40th Annual Meet...

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) – CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 5-9, 2025, in National Harbor, Maryland. Abstract # 640: CHS-114, an ...

October 3, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences: Baird 2025 Global Healthcare Conference in New York, NY on Tuesday, September 9, 2025, at 1:25 p.m. Eastern Daylight Time / 10:25 a.m. Pacific Daylight TimeH.C. Wainwright 27th Annual Global Investment Conference in New York, NY on Wednesday, September 10, 2025, at 11:00 a.m. Eastern Daylight Time / 8:00 a.m. Pacific Daylig...

September 3, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology Reports Second Quarter 2025 Financial Results and Pro...

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update – LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the second quarter ended June 30, 2025 and provided an overview of recent b...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch